Gestational Diabetes Drugs Market Size, Share, and Industry Analysis, By Product Type (Insulin and Oral Anti-Diabetic Drugs), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacies, and Online Pharmacy), and Regional Forecast, 2026-2034

The gestational diabetes drugs market is rising rapidly. Gestational diabetes mellitus (GDM) is a form of hyperglycemia that develops during the gestational period and poses a significant risk to both mother and fetus. Hormonal changes during pregnancy can cause gestational diabetes by affecting the body’s ability to use insulin. 

Genetic makeup and obesity may also contribute to diabetes. The disease can pose a grave risk of preeclampsia, resulting in cesarean delivery and further complications for the fetus. The condition is more common in low- and middle-income countries with limited access to maternal care. It can lead to pregnancy-related complications, including high blood pressure, large birth weight babies, and obstructed labour. Lifestyle changes and medication can help manage the condition. Women over 45 are at greater risk of hyperglycaemia during pregnancy. In contrast, women with a history of GDM have an increased risk of developing type 2 diabetes within five to ten years after delivery. The development of healthcare infrastructure and the increasing prevalence of gestational diabetes to driving the market growth.

• For instance, in October 2022, the Ministry of Health Singapore, on the basis of data from public hospitals, reported that the average number of pregnant women diagnosed with gestational diabetes in public hospitals from 2017 to 2021 was approximately 2,950 each year; such factors are driving the growth of the market.

Gestational Diabetes Drugs Driver

Rising Prevalence of Gestational Diabetes to Augment Demand for Medication and Propel Market Growth

One of the major factors driving the growth of gestational diabetes is the rising prevalence of gestational diabetes worldwide. The sedentary lifestyle, stress, advancing maternal age, and maternal obesity have led to various complications during pregnancy. With the increasing population of expecting mothers with impaired glucose tolerance, the risk of complications such as preeclampsia, cesarean deliveries, and neonatal hypoglycemia heightens. Such a complication creates a need for effective medications. The availability of safer insulin analogs, ensuring reliable blood sugar control, propels the demand for gestational diabetes drugs, thereby driving the overall market growth. 

• For instance, in 2024, the International Diabetes Federation estimated that 23.3 million live births had some form of high blood glucose (hyperglycaemia) during pregnancy.

Estimated Gestational Diabetes Prevalence in Rural and Urban India, 2024

In February 2024, BMC published an article titled ‘National and regional prevalence of gestational diabetes mellitus in India: a systematic review and Meta-analysis’ that reported that the rural population has slightly less prevalence of GDM at 10.0% when compared to the urban population, where the prevalence of GDM was 12.0%.

Gestational Diabetes Drugs Restraint

High Cost of Insulin Analogues to Discourage Product Adoption and Hamper Market Growth

High cost associated with insulin analogues is one of the major factors hampering the growth potential of the market. Such a high cost not only becomes a barrier to the adoption of insulin but also erodes consumer trust due to irrational pricing. The inflated cost of insulin limits accessibility and hampers the overall growth of the global gestational diabetes drugs market. Such high cost despite low production costs led to several lawsuits against key companies.

• For instance, in January 2025, a lawsuit was filed against major insulin manufacturers Eli Lilly, Sanofi, Novo Nordisk, and pharmacy benefit managers, Optum RX, Express Scripts, and CVS Caremark for their unfair and deceptive insulin pricing scheme.

Gestational Diabetes Drugs Opportunity

Emphasis on Development of Antidiabetic Drugs to Offer Lucrative Growth Opportunities in Market

At present, the treatment alternatives are limited to insulin as the only U.S. FDA-approved therapeutic regimen. This unmet need for therapies that are both effective and specifically designed for use in pregnancy offers lucrative growth opportunities—research and Development for novel treatment alternatives, including safer oral agents and innovative insulin delivery systems. As a result, the development of novel pregnancy-specific antidiabetic drugs presents a lucrative growth opportunity for the market, opening avenues for product innovation and regulatory approvals.

• For instance, in March 2025, Eli Lilly and Company launched its diabetes and obesity management drug Mounjaro (tripeptide) in India. Although not pregnancy-specific, the company launched the drug in a single-dose vial following its marketing authorization from the Central Drugs Standard Control Organisation (CDSCO)—such developments to propel the market growth.

Key Insights

The report covers the following key insights:

• Prevalence of Gestational Diabetes, By Key Countries/ Regions
• Pipeline Analysis, By Key Players
• Overview: Standards of Care for Gestational Diabetes
• Key Industry Development (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Product Type

On the basis of the product type, the market is classified into insulin and oral anti- diabetic drugs. 

Among these, insulin is expected to dominate the market segment. The high market share for insulin is attributed to its safety and easy accessibility. It is considered the gold standard for the global gestational diabetes market. Insulin does not cross the intraplacental barrier, thus proving to be a safer alternative, such is the factors to propel the market growth.

• For instance, in July 2024, the American College of Obstetricians and Gynecologists published an article stating that insulin is safe to use during pregnancy as it doesn’t cross the placenta, so it doesn’t affect the fetus.

Analysis by Route of Administration

Based on route of administration, the gestational diabetes drugs market is further divided into oral and parenteral. 

The parenteral segment is expected to dominate the global market during the forecast period. The high segmental share is accredited due to clinical preference, proven safety, and guideline recommendations from ADA and ACOG. Furthermore, product launches of biosimilars of parenterally administered drugs are expected to support the growth.

• For instance, in January 2024, Glenmark Pharmaceuticals Ltd. launched a biosimilar of the anti-diabetic drug Liraglutide in India. The drug has been approved globally for type 2 diabetes mellitus in adult patients in the U.S.

 Analysis by Distribution Channel

On the basis of the distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and online pharmacy.

The hospital pharmacy segment is expected to hold a significant market share. Hospitals act as the first touch point for patient care in gestational diabetes, as it often requires specialized monitoring and intervention by medical practitioners. Most pregnant women with gestational diabetes receive treatment and medication guidance directly through hospital-based care settings. Such centralized and reliable distribution of medications for diabetes acts as a primary channel for dispensing gestational diabetes medications and drives the growth of the segment. 

• For instance, in January 2025, the McDonough District Hospital is expected to unveil its MDH Community Pharmacy. Such developments, facilitating hospital pharmacy operations, propel the growth of the segment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. 

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global gestational diabetes drug market in the forecasted years. The high regional share is attributed to the increasing prevalence of gestational diabetes due to a sedentary lifestyle and poor lifestyle choices—also, the robust healthcare infrastructure, high healthcare expenditure, to drive the growth in the region.

• For instance, the American Diabetes Association reported that gestational diabetes (GDM) affects up to 9.0% of pregnancies in the U.S.

Europe is expected to grow with a considerable CAGR during the forecast period. The region's high growth rate is attributed to increasing integration of digital health technologies and advanced monitoring, reimbursement opportunities, and a strong healthcare ecosystem.

• For instance, in January 2025, Glooko, Inc., received approval for reimbursement by the Haute Autorité de Santé (HAS) and the Commission Nationale d'Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) in France for its Glooko XT solution. This development enabled healthcare providers to receive reimbursement for remote monitoring of gestational diabetes (GDM) in patients not treated with insulin. Such developments assist in collecting precise data and identifying the need for insulin treatment in patients, thus supporting the market growth.

Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The regional growth is attributed to the rising prevalence of gestational diabetes and the advancement in diagnostic and monitoring technologies. Along with these factors, strategic collaboration among key operational entities to drive growth in the region. Such factors support the growth of the gestational diabetes drugs market. 

• For instance, in April 2022, Biocon Biologics was awarded a 3-year contract by the Ministry of Health, Malaysia, for Insugen.

Key Players Covered

The global gestational diabetes drugs market is semi-consolidated with the presence of a few established companies and several other mid-size companies offering diverse product offerings.

The report includes the profiles of the following key players:

• Novo Nordisk (Denmark)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• Merck & Co. (U.S.)
• Abbott (U.S.)
• Dexcom (U.S.)
• Biocon (India)

Key Industry Developments

• In July 2025, Biocon received the U.S. FDA approval for Kirsty (insulin aspart-xjhz) as the first interchangeable biosimilar of Novo Nordisk’s NovoLog (insulin aspart). 
• In July 2024, Novo Nordisk collaborated with Indonesia’s state-owned pharmaceutical company Bio Farma in regards with the packaging of insulin in Indonesia.